Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Randomized Trial
100%
Polycystic Ovary Syndrome
100%
Liraglutide
100%
Thrombogenic Potential
100%
Placebo
44%
Venous Thromboembolism Disease
33%
Cardiovascular Disease
22%
Between-group Difference
22%
Plasminogen Activator inhibitor-1 (PAI-1)
22%
Time to Peak
22%
Lag Time
22%
Endogenous Thrombin Potential
22%
Thrombin Concentration
22%
Cardiovascular Risk
11%
Beneficial Effects
11%
Fibrinolysis
11%
Weight Loss
11%
Insulin Resistance
11%
Later Life
11%
Overweight Women
11%
Placebo-controlled Randomized Trial
11%
Thrombin Generation
11%
5% Weight Loss
11%
Thrombin Generation Assay
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Polycystic Disease
100%
Liraglutide
100%
Thrombin
66%
Placebo
55%
Cardiovascular Disease
33%
Venous Thromboembolism
33%
Obesity
22%
Plasminogen Activator Inhibitor 1
22%
Randomized Controlled Trial
11%
Immunology and Microbiology
Ovary
100%
Thrombin
100%
Fibrinolysis
16%